SCHEMBL6085441

SCHEMBL6085441

CC(C)(C)c1ccc2oc(-c3c[nH]nc3-c3ccc(NC(=O)C(C4CCCCC4)C4CCCCC4)cc3)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.42
MAPT P10636 4/20 0.41
TP53 P04637 2/20 0.41
CETP P11597 6/20 0.41
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
UTRN P46939 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
ALDH1A1 P00352 2/20 0.39
THRB P10828 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085057 0.87 NPC1 (0.51) RXFP1MAPTTP53CETPNPC1
SCHEMBL6085669 0.87 MAPT (0.47) RXFP1MAPTTP53CETPNPC1
SCHEMBL6084904 0.85 NPC1 (0.51) RXFP1MAPTTP53CETPNPC1
SCHEMBL6086097 0.84 NPC1 (0.52) RXFP1MAPTTP53CETPCASP3
SCHEMBL6085988 0.84 CETP (0.44) RXFP1MAPTTP53CETPCASP3
SCHEMBL6085356 0.83 RXFP1 (0.44) RXFP1MAPTTP53CETPCASP3
SCHEMBL6084919 0.83 MAPT (0.56) RXFP1MAPTTP53NPC1RAB9A
SCHEMBL6086007 0.82 AGPAT2 (0.48) RXFP1MAPTTP53CETPCASP3
SCHEMBL6085115 0.82 CETP (0.47) RXFP1MAPTTP53CETPNPC1
SCHEMBL6085392 0.82 CETP (0.45) RXFP1MAPTTP53CETPCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 RXFP1 4580/4885MAPT 801/4885TP53 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.